|
Linda S. Higgins, Ph.D., is the Chief Scientific Officer at InteKrin Therapeutics, Inc. Dr. Higgins joined InteKrin in 2007 and has over 15 years of experience in the pharmaceutical industry. Previously she was with Scios, Inc. where she was most recently Head of Research holding responsibility for drug discovery, preclinical development, and translational medicine. She has led multiple teams for programs in discovery through early clinical development focused on CNS, inflammatory, oncology, cardiovascular, hematology and fibrotic disorders which were advanced internally as well as in partnership with major pharmaceutical companies. During her tenure at Scios, it grew from a discovery organization, to a fully integrated biopharmaceutical company marketing a product discovered in house, to an operating company owned by Johnson & Johnson. Dr. Higgins has authored over 50 original peer reviewed scientific papers and invited reviews, and is inventor on over a dozen patents. She earned an AB in Behavioral Physiology with High Honors and Distinction from Kenyon College, Gambier Ohio; a PhD in Neurosciences from the University of California, San Diego School of Medicine; and postdoctoral training in Molecular Genetics at the Howard Hughes Medical Institute at the University of California, Berkeley. | 